Exploring metabolic adaptation of Streptococcus pneumoniae to antibiotics by Leonard, Anne et al.
The Journal of Antibiotics
https://doi.org/10.1038/s41429-020-0296-3
ARTICLE
Exploring metabolic adaptation of Streptococcus pneumoniae
to antibiotics
Anne Leonard1 ● Kevin Möhlis1 ● Rabea Schlüter2 ● Edward Taylor3 ● Michael Lalk1 ● Karen Methling1
Received: 4 October 2019 / Revised: 31 January 2020 / Accepted: 9 February 2020
© The Author(s) 2020. This article is published with open access
Abstract
The Gram-positive bacterium Streptococcus pneumoniae is one of the common causes of community acquired pneumonia,
meningitis, and otitis media. Analyzing the metabolic adaptation toward environmental stress conditions improves our
understanding of its pathophysiology and its dependency on host-derived nutrients. In this study, extra- and intracellular
metabolic profiles were evaluated to investigate the impact of antimicrobial compounds targeting different pathways of the
metabolome of S. pneumoniae TIGR4Δcps. For the metabolomics approach, we analyzed the complex variety of
metabolites by using 1H NMR, HPLC-MS, and GC–MS as different analytical techniques. Through this combination, we
detected nearly 120 metabolites. For each antimicrobial compound, individual metabolic effects were detected that often
comprised global biosynthetic pathways. Cefotaxime altered amino acids metabolism and carbon metabolism. The purine
and pyrimidine metabolic pathways were mostly affected by moxifloxacin treatment. The combination of cefotaxime and
azithromycin intensified the stress response compared with the use of the single antibiotic. However, we observed that three
cell wall metabolites were altered only by treatment with the combination of the two antibiotics. Only moxifloxacin stress-
induced alternation in CDP-ribitol concentration. Teixobactin-Arg10 resulted in global changes of pneumococcal
metabolism. To meet the growing requirements for new antibiotics, our metabolomics approach has shown to be a
promising complement to other OMICs investigations allowing insights into the mode of action of novel antimicrobial
compounds.
Introduction
In community-acquired pneumonia (CAP), a serious illness
associated with morbidity and mortality [1–4], the most
frequent pathogen isolated in adults is Streptococcus
pneumoniae (the pneumococcus) [5, 6]. S. pneumoniae, a
Gram-positive facultative pathobiont, commonly inhabits
the upper respiratory tract of humans and resulting in at
least 1–2 million infant deaths every year worldwide
[4, 7, 8]. The pneumococcus is a fermentative bacterium
with a high rate of glycolysis [9] and lacks of the Entner-
Doudoroff pathway, aerobic tricarboxylic acid cycle, and
the electron transport chain of aerobe and anaerobe
respiration [9–11]. A challenge in treating pneumococcal
infections is the increasing drug resistance over recent
decades. Currently, 15–30% of the pneumococcal strains
are classified as multi drug resistant [12]. Due to the side
effects of fluoroquinolones the European Medicines Agency
for Europe has emulated the U.S. Food and Drug Admin-
istration in introducing restrictions on their use. Typical
antibiotic therapies of pneumococcus include β-lactams,
macrolides, or fluoroquinolones alone or in combination.
The use of combination therapy of two antibiotics has been
shown to achieve superior outcome compared with mono-
therapy [13–16].
Moxifloxacin is a recently-developed fluoroquinolone
that acts by binding to the topoisomerase enzymes II (DNA
gyrase) thus preventing replication, transcription, and repair
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of bacterial DNA [17]. S. pneumoniae appears to be less
resistant to 8-methoxy quinolone moxifloxacin compared
with earlier fluoroquinolones [18].
The cephalosporins are a group of β-lactam antibiotics.
With a mode of action comparable to penicillin, inhibiting
cell wall synthesis and modification by binding penicillin-
binding proteins (PBPs), this results in arrest of cell growth
and eventual cell lysis of bacteria. PBPs are membrane-
associated enzymes involved in the final step of pepti-
doglycan assembly and turnover [19]. Penicillin allergy is
the most common drug allergy concerning up to 15% of
hospitalized patients, which can present a barrier to treat-
ment of S. pneumoniae infections [20]. Cephalosporines
like cefotaxime were developed to face bacteria resistant to
penicillin or treat infections in humans allergic to penicillin
[21]. Cefotaxime is rapidly deacetylated in the body to
desacetyl cefotaxime, which has a similar antimicrobial
spectrum to cefotaxime [21].
Azithromycin is a macrolide derivative of erythromycin.
The azolide antimicrobial agent is active against pathogens
responsible for infections of the respiratory tract, skin, and
soft tissues in human [22]. Azithromycin inhibits bacterial
growth and replication by interrupting protein biosynthesis
[23].
S. pneumoniae has repeatedly been shown to be capable
of rapidly developing or acquiring resistance to the com-
monly used agents of treating pneumonia. The use of
antibiotic combinations increases the spectrum of targeted
bacterial species in addition to increased efficacy, limiting
the occurrence and spread of resistant bacterial populations.
Many studies focused on the combination of a cephalos-
porin and a macrolide [6, 15, 16, 24, 25].
The rapid development of bacterial resistance to antibiotics
is one of the most recent threats to human health [26]. In the
last 40 years only two new classes of antibiotics have been
discovered [27]. In 2015, the organism, Eleftheria terrae, was
found to produce a novel depsipeptide antibiotic, called
teixobactin [28]. The antibiotic kills a broad range of Gram-
positive bacteria including multi drug resistance strains [28].
There is currently no evidence of acquired resistance. Teix-
obactin binds to the pyrophosphate motifs of multiple bac-
terial cell-wall substrates such as lipid II (precursor of
peptidoglycan) and lipid III (precursor of cell-wall teichoic
acid) [28]. Teixobactin is a naturally occurring molecule and
has a number of issues preventing direct introduction to the
clinic [28, 29]. Parmar et al. designed a synthesis of teix-
obactin analogs that sacrifices antibiotic activity for ease of
synthesis through the replacement of the difficulty to syn-
thesize enduracididine with arginine [29].
Understanding the metabolism of pneumococci is
essential to gain insights into the adaptation strategies that
are required to deal with the host environment during
infection and to identify new drug targets [30]. We analyzed
the metabolic response of S. pneumoniae to limited growth
conditions as well as during treatment with antimicrobial
compounds to identify metabolic adaptation processes. This
study will contribute to a better understanding of pneumo-
coccal physiology. We have used our recently established
workflow [9] to analyze the alterations of extra- and intra-
cellular metabolites of S. pneumoniae after treatment with
different antimicrobial compounds. To cover a broad range
of metabolic adaptations, pneumococci were exposed to
three commonly used antibiotics with different targets of
action (cefotaxime, azithromycin, and moxifloxacin), a
combination of two antibiotics (cefotaxime and azi-
thromycin), and the new antimicrobial compound (teix-
obactin-Arg 10 [29]).
Material and methods
Bacterial strain and growth conditions
The non-encapsulated S. pneumoniae TIGR4Δcps used as
model organism was cultivated in the chemically-defined
medium RPMImodi 1640 (HyClone) [9] and grown on
Columbia blood agar plates (Oxoid) in the presence of the
appropriate antibiotic (150 µg ml−1 kanamycin). The culti-
vation was performed as described previously [9]. At a mid-
exponential phase OD600 of 0.5 the bacterial cells were
treated with either 0.005 µg ml−1 (0.5 × minimal inhibitor
concentration (MIC)) cefotaxime (Sigma-Aldrich),
0.064 µg ml−1 (2 ×MIC) azithromycin (Sigma-Aldrich),
0.8 µg ml−1 (2 ×MIC) moxifloxacin (Sigma-Aldrich),
2 µg ml−1 teixobactin-Arg10 (cooperation with University
of Lincoln, School of Life Sciences [31, 32]), and combi-
nation of 0.5 ×MIC cefotaxime and 2 ×MIC azithromycin
for 90 min. For the control, bacterial cells were cultivated
without antibiotic. We obtained five independent biological
replicates for the metabolome analysis with exception of
teixobactin analog (four independent biological replicates).
Extra- and intracellular metabolome samples were taken at
15, 30, 60, and 90 min (t15, t30, t60, and t90) after the addition
of each antimicrobial compound.
Minimal inhibitory concentration (MIC)
MIC is defined as lowest concentration of a compound/
drug/antibiotic preventing visible growth of a microorgan-
ism [33]. The MIC for each antibiotic compounds was
determined for S. pneumoniae TIGR4Δcps cultivated in
modified RPMI medium (n= 3). The MIC determination
for teixobactin analog was tested only once due to available
restricted amount of compound. At an OD600 of 0.1 each
antibiotic was added to the bacterial main culture in dilution
series. At every hour, the OD600 was measured for 6 h.
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Preparation and 1H NMR spectroscopic analysis
of extracellular metabolites
For the analysis of extracellular metabolites, 2 ml bacterial
cell suspension was filtered and analyzed by using 1H
Nuclear Magnetic Resonance (1H NMR) spectroscopy as
described previously [9].
Preparation of intracellular metabolite extracts
The sampling of intracellular metabolites was described
earlier [9]. In brief, 15 OD units (1 OD units equates 1 ml at
OD600nm of 1) were sampled by using the vacuum-
dependent fast-filtration approach. The filtered cells were
washed twice with 5 ml cold isotonic sodium chloride
solution (130 mM). After the transfer of the filter into
extraction solution (60% ethanol [w/v]), the samples were
shock frozen (liquid N2) and stored at −80 °C prior
extraction. To obtain the intracellular metabolite extracts,
the bacterial cells were washed off the filter by shaking and
vortexing. Resuspended bacteria were transferred into a 50
ml tube containing glass beads with 0.1 mm diameter
(Sartorius AG). The internal standards (see Supplementary
Table S1) for LC-MS and GC-MS analyses were added.
Two cell disruption cycles (2 × 40 s, 6.0 m/s) were per-
formed by using the FastPrep-24 instrument (MP Biome-
dicals). The transfer, washing, and centrifugation of the
bacterial cell extract were described earlier [9]. The super-
natant was diluted with water and stored at −80 °C for
lyophilization. The dried samples were resuspended in
1.5 ml cold water and divided into two equal parts. One part
of each sample was directly frozen and lyophilized for
further GC-MS analysis. 150 µl ice-cold trichloromethane
was added to the other part of the samples. After shaking
and vortexing for ten times the samples were stored at
−20 °C for 5 min and centrifuged at 4 °C and 13,000 rpm
for 5 min. The upper layer of each sample was collected,
frozen, and lyophilized for LC-MS analysis.
HPLC-MS and GC-MS analyses
The measurements of the lyophilized extracts with LC-MS
and GC-MS according to the protocol are described else-
where [9].
The qualitative and quantitative analyses of LC-MS data
were carried out by using DataAnalysis v4.0 and QuantA-
nalysis v2.0 software (Bruker Daltonik GmbH). Absolute
concentrations of metabolites were determined using cali-
bration curves for each metabolite (see Supplementary
Table S2). Signals detected in blank samples were excluded
from the data analysis of biological samples.
For the GC-MS analysis, the identification and quan-
tification of intracellular metabolites were performed
using MassHunter (Agilent). Identification of peaks was
carried out by comparison of retention time and mass
spectra with those of standard compounds in a database
with a similarity of 75% or higher. For quantification, the
areas of the identified peaks were normalized to the area
of peaks of internal standard compounds (see Supple-
mentary Table S2). This ratio represented the relative a-
mount of each metabolite. Absolute concentrations of
metabolites were determined using calibration curves
for each metabolite. Signals detected in blank samples
were excluded from the data analysis of biological
samples.
Determination of the adenylate energy charge
Adenylate energy charge (AEC) was calculated for each
sample using the absolute concentrations of AMP, ADP,
and ATP [34].
Colony forming units (CFU)
Pneumococci were cultivated as described in the cultivation
section above. At t30 and t90 after adding antibiotics, 50 μl of
each culture was transferred into a 1.5 ml micro-reaction
tube that contained 950 μl modified RPMI medium. The
tube was gently swung to ensure an equal dilution. The
dilution step was repeated four times until a dilution factor
of 3.2 × 106 was reached. 50 μl of the final dilution was
spread equally with an inoculation spreader on a blood agar
plate and incubated for 20 h (37 °C/5% CO2). After 20 h,
the colonies were counted.
Transmission electron microscopy
For the transmission electron microscopy (TEM), 15 OD
units were transferred into a 50 ml tube at t90 and cen-
trifugated carefully (3000 rpm, 20 °C, 3 min). The pellet
was washed with 10 ml isotonic NaCl solution and cen-
trifuged again. The cells were fixed with a solution con-
taining 2.5% glutaraldehyde and 2% paraformaldehyde in
buffer (100 mM cacodylate buffer, 10 mM CaCl2, 10 mM
MgCl2, 0.09 M sucrose; pH 7) for 20 min on ice and then
stored at 4 °C until further processing using two different
methods. For method A, cells were embedded in low gelling
agarose, post fixed in 1% osmium tetroxide in buffer for 1 h,
and then stained en bloc with 2% uranyl acetate in 0.9%
sodium chloride for 30 min at room temperature. For
method B, cells were treated with 0.5% glutaraldehyde and
1% osmium tetroxide in buffer for 1 h at 4 °C. Subsequent
to embedding in low gelling agarose, cells were fixed with
1% osmium tetroxide in buffer for 1 h at room temperature,
and then stained en bloc with 0.5% uranyl acetate in 0.9%
sodium chloride at 4 °C overnight.
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For both methods, specimens were then dehydrated in
graded series of ethanol (30–100%) on ice for 30 min each
step, and finally the material was stepwise infiltrated with
the acrylic resin LR White according to Hammerschmidt
et al. [35]. Sections were cut on an ultramicrotome (Reichert
Ultracut, Leica UK Ltd, Milton Keynes, UK), stained with
4% aqueous uranyl acetate for 5 min and analyzed with a
transmission electron microscope LEO 906 (Carl Zeiss
Microscopy GmbH, Oberkochen, Germany). The micro-
graphs were edited by using Adobe Photoshop CS6.
Statistics and visualization
Statistical analysis and visualization of data were carried out
by using the Prism v7 software (GraphPad). The p values
were calculated based on two-way ANOVA and sig-
nificance level of 0.05 was corrected for multiple testing by
Šidák. Color-coded heat maps were created with MeV
(v4.9). The changes in the extracellular metabolome were
analyzed by fold change (FC) calculation of concentrations
of each metabolite for each time point relative to the control
at the corresponding time point and normalization to the
optical density measured at the respective sampling time
(see Table S3 in Supplementary material). For the intra-
cellular metabolome there was a normalization step in the
sampling protocol. Always 15 OD units of bacteria were
sampled and divided into equal parts after extraction for
analysis by HPLC-MS and GC-MS.
Results
Inventory of pneumococcal metabolic profile
To analyze the metabolic adaptation of S. pneumoniae
TIGR4Δcps to different antimicrobial compounds, bacterial
cells were exposed to antibiotics during exponential growth
phase. The fast doubling time of the bacteria during this
phase ensures a fast turnover of metabolites in the bacteria
and thus excellent conditions to study the influence of
certain antibiotics on the pneumococcal metabolome. Extra-
and intracellular metabolome samples were taken in a time
span of 2 h (starting point OD of 0.5) to observe fast and
time-resolved alterations. The largest growth difference
between control and drug treatment was observed 90 min
after adding the antimicrobial compounds (Fig. 1a). In
addition to MIC determination (see Fig. S1 in Supplemen-
tary material), the CFU were counted (see Fig. S2 in Sup-
plementary material). Furthermore, stressed and control
bacteria were examined by transmission electron micro-
scopy at t90 after antimicrobial stress, to highlight which
morphological variations may be linked to alterations within
the metabolome (Fig. S3). The cell wall was only altered in
cells stressed by moxifloxacin and teixobactin-Arg10 (Fig.
S3). Bacterial cells treated with teixobactin-Arg10 pre-
sumably showed a defective cell wall and thus cell com-
ponents escaped from the cells. In addition, all stressed cells
with exception of cells treated with azithromycin showed
more and longer white areas inside compared with control.
In the control cells and cells stressed with azithromycin the
areas were very weak.
The AEC was determined for each sample. In this study,
the AEC was 0.84 ± 0.02 for pneumococcal cells under
control and stress conditions (Fig. 1b).
Using 1H NMR spectroscopy, HPLC-MS and GC-MS,
124 compounds were identified and analyzed (see Supple-
mentary material Tables S3–S6) to cover a broad range of
the chemically diverse metabolites. By using 1H NMR, 37
metabolites were identified and quantified by using a library
of standard spectra. Quantification of 90 metabolites by GC-
MS and HPLC-MS was verified by using labeled analytical
standard compounds (see Supplementary Table S2). In
summary, different metabolic pathways such as glycolysis,
the pentose phosphate pathway, peptidoglycan biosynthesis,
Fig. 1 Growth curves (a) of S. pneumoniae TIGR4Δcps in RPMImodi
and adenylate energy charges (b). Curves and columns are colored
according to the antibiotic stresses: control (black), cefotaxime
(yellow), azithromycin (blue), combination of cefotaxime and azi-
thromycin (green), moxifloxacin (orange), and teixobactin-Arg10
(gray). Data are shown as mean values ± standard derivation (n= 4–5)
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purine and pyrimidine nucleotide metabolism, cofactor and
amino acid metabolism were affected (Table 1). Two kinds
of metabolic changes were observable: on the one hand
time-dependent metabolic alterations and on the other hand
antibiotic stress-dependent changes were visible.
Cefotaxime treatment dependent metabolic
alterations
The treatment of pneumococci with cefotaxime changed
significantly the levels of 63 intracellular metabolites com-
pared with control conditions. Thereof, 32 metabolites were
increased in amount (Table 1). Cefotaxime as inhibitor of
cell wall synthesis caused significant decrease in amounts of
cell wall precursors UDP-GlcNAc, GlcNAc-6-P, and UDP-
MurNAc-Ala-Glu-Lys at t90 (Fig. 2). Surprisingly, strong
effects of cefotaxime stress were found for glycolysis, amino
acid, and nucleotide metabolism. The levels of all glycolytic
metabolites following 1,3-bisphosphoglycerate (1,3-bP-gly-
cerate) were enhanced compared with control at t15. Increase
in amount of pyruvate was also more than twofold, but not
significant (p > 0.05) (Fig. 3). The enhanced intracellular
pyruvate concentration may cause the observed changes in
the amount of associated metabolites as observed for alanine
as well as acetyl-CoA and lactate (both p > 0.05). The
intracellular concentration of alanine was increased at t15 and
Fig. 2 Intermediates of peptidoglycan biosynthesis of S. pneumoniae
TIGR4Δcps. Relative amounts of intracellular metabolites are pre-
sented as bar charts. Columns (n= 4–5) are colored according to the
antibiotic stresses: control (black), cefotaxime (yellow), azithromycin
(blue), combination of cefotaxime and azithromycin (green),
moxifloxacin (orange), and teixobactin-Arg10 (gray). Asterisks indi-
cate significant differences (α= 0.05 after Sidak correction) between
the treated cells and the control. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001;
****p ≤ 0.0001
Table.1 Table showing numbers of intracellular metabolites significantly changed in amounts (p ≤ 0.05)
Cefotaxime Azithromycin Cefotaxime+
azithromycin
Moxifloxacin Teixobactin-Arg10
Increased Decreased Increased Decreased Increased Decreased Increased Decreased Increased Decreased
Carbon metabolism 9 5 2 3 13 4 6 4 8 4
Amino acid metabolism 17 2 1 3 18 2 4 2 11 5
Nucleotide metabolism 2 18 0 15 3 18 11 10 2 20
Cell wall precursors 2 4 1 5 4 3 4 2 5 3
Other intermediates 2 2 0 2 3 5 4 1 3 4
Total 63 32 73 48 65
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t30 under stress conditions. Phenylpyruvate and the related
metabolite tyrosine showed the same effects intracellularly.
Amount of tyrosine increased threefold at t15. Also, the
amounts of aspartate, asparagine, and threonine were
enhanced at t15 intracellularly. Moreover, glutamine and
related metabolites like glutamate, 2-oxoglutarate and pro-
line, possessed the same intracellular metabolome adapta-
tions with FC ≥ 3 for all metabolites (Fig. 3).
The majority of analyzed nucleotides were significantly
decreased in amount intracellularly at t90 (Fig. 3), which
appears to be a general effect of all stress conditions with
exception of DNA gyrase inhibitor moxifloxacin. Only the
amount of GTP (p > 0.05) showed no changes compared
with control conditions. The amounts of GDP and IMP
(both p > 0.05) decreased compared with control. Twofold
higher concentrations were found for the nucleobases ade-
nine and uracil at t15 compared with control conditions. In
conclusion, intracellular amounts of glycolysis metabolites
and amino acids were changed at t15 and nucleotides were
altered mostly at t90 after stress induction.
Macrolide azithromycin
In general, the treatment with azithromycin caused least
metabolic alterations compared with the other tested
antibiotics. In total, abundances of 32 metabolites were
influenced significantly compared with untreated pneu-
mococci. Although, four intracellular metabolites showed
a significant increase and 28 metabolites a decrease in
amount (Table 1). Pneumococci stressed with azi-
thromycin showed no significant changes in amino acid
metabolome with exception of altered levels of methio-
nine, lysine, and isoleucine, which were influenced the
same way by all other antibiotic treatments in this study.
2-Oxoglutarate as intermediate of glutamine/glutamate
metabolism was increased two- to five-fold in amount
intracellularly at all time points (Fig. 3). Also, glycolysis
was less affected compared with other stress conditions.
Glycolytic metabolites like fructose-1,6-bisphosphate
(frc-1,6-bP) and phosphoenolpyruvate (PEP) showed
enhanced concentrations 90 min after adding azi-
thromycin (t90) (Fig. 3). Both, pyruvate as end product of
glycolysis and the fermentation product lactate were
found in similar amounts as in control samples.
The inhibitor of protein synthesis azithromycin
decreased significantly the amounts of all detected intra-
cellular purine and pyrimidine metabolites at t90 (XMP
(p > 0.05)) (Fig. 3). Only the purine nucleotides GDP,
GTP, and IMP seems to be not affected after azithromycin
stress.
Fig. 3 Intracellular metabolites of (a) purine and pyrimidine metabo-
lism, (b) carbon metabolism, and (c) amino acid metabolism of
S. pneumoniae TIGR4Δcps. The illustrated heat maps with fold
changes (FC) of metabolite concentrations under conditions of anti-
biotic treatment referred to control shows metabolites with increased
concentrations compared with unstressed bacteria in yellow and with
decreased concentrations in blue at the different time points (t15–t90).
Gray fields: metabolites were not detected under stress and/or control
conditions
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Treatment with the combination of antibiotics—
cefotaxime and azithromycin
After pneumococcal exposure to cefotaxime and azi-
thromycin, the intracellular abundances of 73 metabolites
were significantly changed compared with control cells.
These included 41 increased and 32 decreased metabolites.
Bacterial treatment with the combination of the antibiotics
induced the largest changes in the metabolome compared
with other antimicrobial stress conditions. Surprisingly,
seven metabolites showed significant changes only by
treatment with combination of the two antibiotics azi-
thromycin and cefotaxime and not by single usage: threo-
nine (t90), 4-P-pantothenate (t15 and t30), acetyl-CoA
(t15–t60), malonyl-CoA (t15), glutathione disulfide (GSSG)
(t15), UDP-MurNAc (t60), and UDP-MurNAc-Ala (t90)
(Figs. 2, 3). Also, UDP-MurNAc-Ala-Glu-Lys-Ala-Ala
showed increased amount (p > 0.05) at t90, which is contrary
to the alternations by treatment with cefotaxime only. Other
noticeable effects of combination treatment were intensified
glycolytic metabolic alterations compared with single
usage. The amounts of 1,3-bP-glycerate and following
metabolites of glycolysis until pyruvate were significantly
increased, as well as amounts of phenylpyruvate, lactate,
acetyl-CoA, and malonyl-CoA.
The changes in the intracellular amino acid metabolism
caused by the treatment with cefotaxime were also found in
the combination treatment with cefotaxime and azi-
thromycin. Furthermore, all detected nucleotides with
exception of GDP and GTP showed a decreased intracel-
lular abundance, which was comparable to cefotaxime
stress. Furthermore, similar effects were observed for ade-
nine and uracil (Fig. 3).
In summary, cells stressed by combined treatment mostly
showed metabolic changes similarly to cells stressed with
cefotaxime (Fig. 3).
DNA gyrase inhibitor moxifloxacin
The fluoroquinolone moxifloxacin had a significant effect
on the amounts of 48 metabolites. The abundances of 29
metabolites were increased and 19 metabolites were
decreased.
Most alterations were found for the purine and pyr-
imidine nucleotide metabolism. Levels of adenine, AMP, 2-
dADP, 2-dATP, uracil, and the di- and triphosphates of
uridine, cytidine, and guanosine were increased intracellu-
larly. Reduced amounts of the other detected nucleotides
were found after antibiotic treatment compared with control
cells with exception of 2-dTMP, AMP, CMP, and UMP
showing no changes (Fig. 3).
Intermediates of glycolysis such as 3-phosphoglycerate
(t30, t60, and t90), 2-phosphoglycerate (t30, t60), PEP (t90), and
pyruvate (t15) were increased. Pneumococci treated with
moxifloxacin showed alterations in several amino acids like
leucine, proline, glycine, serine, threonine, aspartate, glu-
tamate, tryptophan, and more (p > 0.05) (Fig. 3). Changes of
concentration of cell wall metabolites were also detected
(Fig. 2). The amount of UDP-GlcNAc was increased sig-
nificantly at t15–t60 and UDP-GlcNAc-enolpyruvate (t90)
and GlcNAc-6-P (t30) were decreased. We found that
pneumococci stressed with moxifloxacin contained
enhanced concentrations of three building blocks of teichoic
acids namely glycerol-1-phosphate, CDP-ribitol (both p <
0.05 at all time points), and CDP-choline (p > 0.05) (Fig. 3).
As specific as in the case of the building blocks for teichoic
acids, abundance of 4-P-pantothenate was increased in the
cells at t15 and t30 after stress induction.
Teixobactin-Arg10 stress metabolic alterations
The lipid II binder teixobactin-Arg10 caused alterations in
concentrations of 65 pneumococcal metabolites compared
with control. Amounts of 29 metabolites were increased and
36 metabolites decreased significantly. Teixobactin-Arg10
caused enrichment of cell wall precursors UDP-MurNAc,
UDP-MurNAc-Ala-Glu-Lys, and UDP-MurNAc-Ala-Glu-
Lys-Ala-Ala and also influenced concentrations of other
intermediates of peptidoglycan synthesis such as GlcNAc-
6P, UDP-GlcNAc, and UDP-GlcNAc-enolpyruvate (Fig. 2).
Abundance of glycerol-1-phosphate was increased from t15
to t60 after stress induction.
The intracellular amounts of glycolysis intermediates
and lactate were increased in pneumococci shortly after
stress induction e.g., phosphoenolpyruvate (p > 0.05) and
pyruvate at t15 and t30 after treatment and phenylpyruvate,
as well as acetyl-CoA at t15. However, 90 min after stress
induction the level of pyruvate was decreased compared to
control conditions (Fig. 3). Increased concentrations were
also detected for pyruvate extracellularly (Fig. 4). Another
effect of the teixobactin analog was observed in the chan-
ged arginine-ornithine antiporter regulation. Ornithine
secretion stopped after treatment with teixobactin-Arg10,
but uptake of arginine was unchanged compared to control
and other stress conditions (Fig. S4). In summary,
teixobactin-Arg10 caused most metabolic changes in the
exometabolome, for example observed for phenylalanine
(t15 and t60), tyrosine (t15), serine (t15), asparagine (t15).
Levels of amino acids like glycine, serine, tyrosine, proline,
aspartate and asparagine were increased intracellularly
shortly after beginning of stress (t15–t30). The same obser-
vations were made for glutamine and leucine (p > 0.05).
Uptake or secretion of amino acids was not influenced. In
contrast concentrations of most amino acids dropped down
intracellularly under stress conditions compared to control
at t90 (p > 0.05) (Figs. 3, 4).
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Among the 36 metabolites with decreased amounts were
many purine and pyrimidine metabolites, for instance all
detected nucleotides and deoxy nucleotides showed lower
concentrations at t60 and t90 after teixobactin-Arg10 stress
when compared to the control. Also, lower abundance was
found for 6-phosho gluconate. Only adenine (p < 0.05 for
all time points) and uracil (p < 0.05 for t15–t60) level were
increased intracellularly compared to control conditions
(Fig. 3).
General stress-dependent metabolic changes
The amounts of amino acids and cell wall precursors as
well as nucleotides were altered in pneumococci by all
stress conditions. The intracellular methionine amount
was increased at t15 and t30. In contrast, other amino acid
concentrations were reduced at t90 e.g., concentrations of
lysine, isoleucine (both p < 0.05), glutamine and ornithine
(both p > 0.05). The amounts of the nucleotides ADP,
ADP-ribose, ATP, c-di-AMP, GMP, UMP, 2-dCTP, 2-
dTDP and 2-dTTP decreased intracellularly during all
stress conditions at t90 (Fig. 3). Furthermore, levels of
ribose-5-P, malonyl-CoA and UDP-GlcNAc-enolpyruvate
decreased intracellularly at t90 (Figs. 2, 3). A general
increase in concentration was only observed for NADP+
at all time points with exception of treatment with azi-
thromycin causing only increase in NADP+ level at t90
(Fig. 3).
Discussion
The traditional therapies for pneumococcal-induced pneu-
monia include β-lactam, macrolide, fluoroquinolone and
tetracycline antibiotics [36]. Resistance to penicillin and
macrolide antibiotics in S. pneumoniae has increased in
many areas [37]. Small molecules like antibiotics can have
pleiotropic effects on bacteria, which was demonstrated in
our study. Our investigations were focused on the non-
encapsulated strain S. pneumoniae TIGR4Δcps. Specific
differences in metabolism of S. pneumoniae strains have to
be considered for a generalization of our results. We used
antimicrobial compounds with classical and novel targets
towards the bacterial metabolism at a single concentration
to cover a broad range of responses in metabolic pathways.
Including this study, several OMICs studies have been
performed to demonstrate the effect of antibiotics on
pneumococcal physiology [38–45].
Impact of antibiotics as general metabolic changes
The AEC as ratio of ATP, ADP, and AMP describes the
energy balance of cells. In living cells, the AEC is near
0.85, if the formation of ATP is controlled primarily by the
concentration of the regulatory end product [46]. Chapman
et al. showed that depletion of the carbon source glucose
caused a decreased AEC in Escherichia coli [47]. In this
study, during the whole experiment pneumococci had no
Fig. 4 Extracellular metabolites of S. pneumoniae TIGR4Δcps. The
illustrated heat map with fold changes (FC) of metabolite amounts
after addition of antibiotics referred to control conditions both with
normalization to optical density (600 nm) shows metabolites with
higher concentrations compared to control in yellow and with lower
concentrations in blue at the different time points (t15–t90). Gray fields:
metabolites were not detected under stress and/or control conditions
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limitation of glucose. At t90 after antibiotic treatment, about
22 mM glucose was available for the bacteria. The antibiotic
treatment caused reduced levels of adenosine nucleotides
but not affected the resulting AEC, so energy balance of the
bacteria seems not to be influenced.
General, the effect of enhanced amino acid levels is
described to be a stress response of S. pneumoniae to anti-
biotics [10, 48]. Bacterial stress mechanisms induce an
increased synthesis of amino acids, which are precursors for
protection proteins like CodY [49]. Methionine is essential
for growth of pneumococcal cells [10, 50] and intracellular
methionine concentration was increased immediately after
initiation of stress conditions. Methionine is involved in
many anabolic reactions like protein biosynthesis, N-for-
mylmethionine formation and S-adenosylmethionine synth-
esis. Studies showed that a mutation of the MetQNP ABC-
transporter and the methionine synthetase metQ/metEF
induced an inhibition of pneumococcal growth [50, 51].
S. pneumoniae might show an adaptation in the metabolism
in raising the level of methionine to protect the cells.
The intracellular level of c-di-AMP significantly
decreased in all stressed cells at t90 after addition of anti-
biotics. For Staphylococcus aureus a very low level of c-di-
AMP is supposed to contribute to reduced bacterial growth
rate [52]. Cell wall biosynthesis seems to be affected not
only by specific inhibitors like cefotaxime because diverse
effects on synthesis of cell wall precursors were observed
for all antibiotics. However, all stress conditions led to
significant reduction in levels of the cell wall precursor
UDP-GlcNAc-enolpyruvate. This might be connected with
a general influence of antibiotic treatment on glutamine
metabolism of S. pneumoniae resulting in decreased level of
glutamine and Glc-NAc-6-P at t90.
Another general effect seems to be a downregulation of
PPP providing reduction equivalents by reducing NADP+.
NADP+ was detected in increased amounts and ribose-5-
phosphate, as another important product of PPP, in
decreased amounts after all stress conditions. Lower level of
ribose-5-phosphate as precursor of nucleotide biosynthesis
might be connected with dropping of nucleotide amounts at
t90. Increased amounts of NADP
+ were shown in S. aureus
among different antibiotic treatments only with fluor-
oquinolone ciprofloxacin [53].
Impact of cephalosporin cefotaxime on the
metabolism of S. pneumoniae
Metabolic response of S. pneumoniae to cefotaxime showed an
increased amount of glutamine and glutamate intracellularly.
Glutamine is major nitrogen donor for purine and pyrimidine
biosynthesis and for the synthesis of the cell wall precursors.
Glutamine is used by the aminotransferase GlmS to convert
fructose-6-P into glucosamine-6-P [54, 55]. As shown in S.
aureus inhibition of GlmS correlates with a broad set of cell
wall synthesis inhibitors [56]. Transcriptional response of S.
pneumoniae to penicillin showed decreased glutamine meta-
bolism. The most downregulated genes encode ABC trans-
porter GlnQ, the transcriptional regulator GlnR, and the
glutamine synthetase GlnA [38]. Enhanced intracellular con-
centrations of glutamine and glutamate as described for S.
pneumoniae after penicillin treatment [38] were also observed
after exposure to cefotaxime in this study whereas uptake of
glutamine and glutamate was not influenced. Interestingly, it
was shown that glutamine protects S. pneumoniae against
penicillin stress [38]. The inhibition of GlmS in methicillin-
resistant S. aureus [56] and of GlnA in penicillin-resistant S.
pneumoniae [38] decreased their level of resistance. Glutamine
is also a cofactor for the cross-linking of the peptidoglycan by
MurT/GatD [57]. Our results showed that cefotaxime influ-
enced the amounts of four peptidoglycan precursors reaffirm-
ing the known mechanism of action of cephalosporins [58].
Increased amounts of threonine were detected in pneu-
mococcal stress response. Threonine is part of the active site
of penicillin binding protein 2 × (PBP2x). After binding of
cefotaxime to PBP2x, threonine has directly contact with
the cephalosporin [59]. Loss of the hydrogen bond between
cefotaxime and threonine is known to induce resistance
[60]. Thus, threonine could be a crucial metabolite in for-
mation of resistance. In this study, cefotaxime stress
increased the amount of threonine intracellularly.
The results of the metabolome analysis revealed varia-
tions of peptidoglycan biosynthesis. Therefore, the pneu-
mococcal cell morphology was investigated and visualized.
The cell wall was not affected in thickness or morphology.
Conspicuously were the white areas in the TEM images.
Hoyer et al. could show similar effects depending on
medium composition that also strongly influenced the pro-
tein expression in S. pneumoniae [61]. The areas in the
TEM images could be granular of a storage substance that
was not detectable by metabolome analysis. Poly-β-
hydroxybutyrate (PHB) is an intracellular storage material
found in Lactobacillus, Lactococcus, Pediococcus, and
Streptococcus species. The bacteria accumulate PHB during
the stationary phase of growth [62]. However, for
S. pneumoniae PHB is hitherto unknown.
Impact of macrolide azithromycin on the
metabolism of S. pneumoniae
Macrolides have shown some strong anti-inflammatory
effects [63], reducing the release of IL-8 and TNF-α. Also
macrolides inhibit effective adherence of bacteria to
respiratory epithelial cells and so decrease the production of
virulence factors [64]. It has been demonstrated that azi-
thromycin blocks peptide biosynthesis resulting in a
reduced uptake of amino acids from the medium [53]. Our
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findings showed no significant changes of amino acid
uptake and intracellular concentrations by azithromycin
stress. Interestingly, macrolides can be secreted by ATP
dependent efflux pumps from pneumococcal cells [65, 66].
A study using E. coli has suggested a physical interaction
between macrolide efflux proteins Mef(E) and Mel, binding
of macrolides to Mel and localization to the membrane [67].
Induction of efflux proteins occurs very fast after exposure
to different macrolide antibiotics [68]. Efflux of antibiotics
could be a reason that S. pneumoniae showed least meta-
bolic alteration caused by azithromycin compared with
other stress conditions. In this study, azithromycin treatment
of S. pneumoniae influenced the purine and pyrimidine
biosynthesis as also proved for S. aureus [53, 69]. These
results suggested that the bacterial cells responded to azi-
thromycin by reducing generation of nucleotides and
resources for DNA synthesis [69].
Impact of combination of cefotaxime and
azithromycin on the metabolism of S. pneumoniae
A drug combination therapy is increasingly used in the
hospitals because of better coverage in polymicrobial CAP.
It has been suggested that S. pneumoniae-induced pneu-
monia patients have concomitant Mycoplasma pneumoniae
or Legionella sp. infections [6, 63]. Combination therapy
acts at two different sites in bacteria i.e., the inhibition of
cell wall biosynthesis by β-lactams, and inhibition of pro-
tein synthesis by macrolides. Our study showed for the first
time metabolome adaptations of S. pneumoniae to com-
bined stress of cefotaxime and azithromycin. Combined
application of these two antibiotics resulted in a largest
change in the metabolome of S. pneumoniae compared to
the other antimicrobial treatments. Comparable metabolic
changes were observed when cefotaxime was applied
solely, e.g., on amino acid metabolism. But combination
treatment seemed to intensify the effects on glycolysis and
lactate formation as well as nucleotide biosynthesis com-
pared to cefotaxime alone. However, there were also sig-
nificant changes of seven metabolites only caused by the
combined treatment with cefotaxime and azithromycin.
Probably these additional effects on the pneumococcal
metabolism could be a reason for better outcome of CAP
patients. Glutathione is used as a marker of oxidative stress
[70]. Only after treatment with cefotaxime and azithromycin
an altered level of oxidized glutathione (GSSG) was found.
Impact of fluoroquinolone moxifloxacin on the
metabolism of S. pneumoniae
The treatment of S. pneumoniae with moxifloxacin causes
double-stranded breaks in the bacterial chromosome [42]
and requires active protein synthesis [71]. Treatment with
moxifloxacin was reported not altering the level of global
supercoiling [42]. Moxifloxacin induces transcriptional
changes, which ultimately stimulate the Fenton reaction,
increasing ROS accumulation and contributing to cell death
[42]. S. pneumoniae treated with the fluoroquinolone
induces upregulation of the fatDCEB operon coding an iron
transporter. Subsequently, the intracellular iron concentra-
tion increased leading to accumulation of ROS [72]. De la
Campa et al. reviewed that for the facultative anaerobic
bacterium, S. pneumoniae, the increased lethality of fluor-
oquinolones is mediated by an increase in ROS fiting
with the antibiotic lethality model proposed for aerobic
bacteria [40].
The transcriptomic response of S. pneumoniae R6 to
moxifloxacin led to an upregulation of metabolic pathways
involved in the production of pyruvate [42]. Similar to
Ferrandiz et al. which showed an increase in acetyl-CoA
[42], our study demonstrated also increased abundances of
glycolytic intermediates and pyruvate. Interestingly, acetyl-
CoA showed no altered level compared to the control in this
study but increase in amount of acetate extracellularly. The
inhibition of DNA and RNA synthesis led to a block in
septum formation and a more thickened cell wall [73].
Morphological changes of cell wall could be confirmed in
our study. In S. aureus, a downregulation of metabolism on
transcriptomic level was found by treatment with the
fluoroquinolone ciprofloxacin, including purine and pyr-
imidine biosynthesis [69]. Furthermore, in S. aureus an
increase of nucleotides and nucleosides was detected [53].
Also genes of purine and pyrimidine biosynthesis were
upregulated in S. pneumoniae R6 treated with moxifloxacin
[42]. Both fits well with our results, nearly half of all
detected nucleotides were increased in amounts sig-
nificantly in S. pneumoniae cells under moxifloxacin stress.
Changed levels of cell wall intermediates as observed for
Streptococcus faecalis [73] were also detected in our study.
CDP-ribitol was significantly influenced only by moxi-
floxacin treatment, so it could function as a marker of
moxifloxacin stress in our study. Increased amounts of CTP
might be connected with the enhanced level of CDP-ribitol.
Further investigations of S. pneumoniae on metabolome
level are necessary including all other antibiotic drug clas-
ses to confirm this metabolite as marker.
Impact of Arg10 teixobactin on the metabolism of S.
pneumoniae
The need for new antibiotics for treatment of resistant
pathogens become a major global concern for human health.
The isolation of teixobactin in 2015 by Ling et al. raised
great expectations [74]. It was one of a few novel antibiotics
that have been reported in recent years showing no resis-
tance development [28]. The naturally occurring molecule,
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teixobactin, has the same limitations due to the low yield
[29]. Pamar et al. designed and synthesized potent teix-
obactin analogs [31, 75]. This was the first study that
investigated the effects of a teixobactin analog on bacterial
metabolism by using teixobactin-Arg10. Lipid II as one of
the known targets of teixobactin is removed from the
cytoplasmic membrane prior to incorporation of its
disaccharide-peptide moiety into peptidoglycan [76]. The
binding of teixobactin prevents the removal of lipid II. The
pyrophosphate group and the attached first sugar subunits of
lipid II was found to be a minimal motif for stabile teix-
obactin binding [77]. In our study, we observed an accu-
mulation of the three peptidoglycan precursors UDP-
MurNAc, UDP-MurNAc-Ala, and UDP-MurNAc-Ala-Glu-
Lys-Ala-Ala confirming the inhibition of peptidoglycan
synthesis in S. pneumoniae treated with teixobactin-Arg10.
Formation of excrescence found in transmission electron
micrographs of S. pneumoniae TIGR4Δcps cells pointed out
changes in cell wall morphology. Teixobactin has an effect
on cell morphology and destroyed cell wall integrity in
S. aureus [78]. Our observations confirmed these results for
S. pneumoniae TIGR4Δcps treated with the teixobaction
analog.
The main metabolic pathway of S. pneumoniae is gly-
colysis [48]. Therefore, influences on glycolysis should be
significant and changes are expected in metabolome. It is
possible that increase of glycolysis intermediates indicates a
stress response in this study. However, 90 min after anti-
microbial stress, glycolysis metabolites are present in a
decreased concentration compared with unstressed cells.
Possibly the metabolism is downregulated by stress and
consequently less energy is available.
Another interesting outcome was that the extracellular
level of ornithine was influenced by the stress induced by
teixobactin-Arg10. Arginine-ornithine antiporter (ArcD) is
essential for the virulence of S. pneumoniae TIGR4 [79].
Arginine is one of the amino acids that cannot be synthe-
sized de novo and has to be taken up by pneumococcus
[9, 48]. Uptake of arginine was unaffected but ornithine
secretion was completely stopped by treatment with the
teixobactin analog. Gupta et al. assumed another function
for ArcD that affects the linkage of the capsular poly-
saccharide to pneumococcal cell wall [80], however, this
aspect is not relevant for the non-encapsulated S. pneumo-
niae TIGR4Δcps. The deletion of arcD reduces the amount
of capsule materials on the bacterial surface. ArcD appears
to play different roles in the pathogenicity of various
pneumococcal serotypes, as the deficiency of ArcD in
another strain does not affect the capsule [80, 81].
Pyrimidine nucleotides play an important role in the
biosynthesis of activated nucleotide sugars (NDP-sugars).
NDP-sugars are precursors for the synthesis of exopoly-
saccharides and peptidoglycan in lactic acid bacteria [82].
Carvalho et al. proposed a link between pyrimidine meta-
bolism and capsule biosynthesis in S. pneumoniae D39
[83, 84]. Also they showed that uracil affects the pneumo-
coccal capsule [85]. In our study, uracil concentration
intracellularly increased after antibiotic stresses (teix-
obactin-Arg10, moxifloxacin, cefotaxime, and combination
of cefotaxime and azithromycin) and adenine concentration
showed same changes. Cultivation medium was supple-
mented with both nucleobases, but uptake was not enhanced
compared with control. Due to the use of non-encapsulated
S. pneumoniae TIGR4, in our study uracil was not asso-
ciated with capsule formation. High amounts of nucleobases
and decreased level of nucleotides might refer to intensified
degradation of nucleotides or inhibition of salvage path-
ways of nucleotide formation as an outcome of reduced
growth.
Conclusion and outlook
The presented study showed intra- and extracellular meta-
bolic changes of S. pneumoniae TIGR4Δcps stressed by
different antimicrobial compounds. Possibly there are lim-
itations in this approach resulting from the usage of only a
single strain of S. pneumoniae and antibiotic concentration.
Based on our findings, future investigations on metabolic
adaptions of S. pneumoniae to antibiotic treatment should
include different S. pneumoniae strains to exclude strain-
specific reactions. The use of resistant bacteria utilizing
resistance to a specific antimicrobial compound or com-
pound class may allow to verify metabolic alterations to
antibiotic stress in nonresistant strains. Furthermore, chal-
lenging bacteria with different concentrations of antibiotics
could be helpful to study dose-dependent changes in
metabolism.
No antibiotic showed a single alteration of a spe-
cific metabolite or a specific metabolic pathway in pneu-
mococcal cells but rather a globally affected metabolome.
Distinctive pathways affected were the purine and pyr-
imidine metabolism and the peptidoglycan biosynthesis as
well. The fluoroquinolone moxifloxacin altered the
nucleotide metabolism and teichoic acid precursors in a
specific way. Typical for treatment with cefotaxime were
enhanced levels of glutamine and glutamate and altered
peptidoglycan metabolism. The fewest changes in the
metabolome were caused by treatment with azithromycin,
only remarkable changes in nucleotide metabolism were
observed. A combination of cefotaxime and azithromycin
resulted in metabolic variations mostly comparable to the
application of cefotaxime alone. The teixobactin-Arg10
influenced level of peptidoglycan precursors as well as
nucleotides and the arginine–ornithine antiporter. Given the
broader global effects of the synthetic teixobactin analog on
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the metabolome of pneumococcal cells, it potentially pro-
vides a starting point for a new antibiotic treatment strategy.
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